Longeveron Inc. (LGVN) Stock Price & Analysis
Longeveron Inc. (LGVN) fell 1.19% to USD 0.6 as of July 25, 2026 at 03:51 UTC, according to Nexqual real-time market data.
LGVN last closed at USD 0.61; the session ranged USD 0.59–0.63 on volume of 157,171 shares. Market capitalization is $18.96M, with a 52-week range of USD 0.48–1.75 (NCM). Source: Nexqual, July 25, 2026 at 03:51 UTC.
Key Statistics (as of July 25, 2026 at 03:51 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 1.19% (down) |
| Previous Close | USD 0.61 |
| Open | USD 0.62 |
| Day Range | USD 0.59 – 0.63 |
| 52-Week Range | USD 0.48 – 1.75 |
| Volume | 157,171 shares |
| Market Cap | $18.96M |
| Exchange | NCM |
Technical Analysis (LGVN)
Nexqual's technical model rates LGVN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.89 (neutral) |
| vs SMA50 | Below (USD 0.72) |
| MACD | -0.04 (negative) |
Analyst Ratings (LGVN)
Wall Street analysts rate LGVN "None" based on 3 analysts, with a mean price target of USD 7.15 (range USD 3–10.45), per Nexqual as of July 25, 2026 at 03:51 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 7.15 |
| High Target | USD 10.45 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (LGVN)
| Next Earnings Date | 2026-08-12 |
|---|---|
| Revenue Estimate | $326,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.17 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.39 vs est -0.26 ▼ miss |
| 2025-06-30 | USD -0.33 vs est -0.35 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financials & Fundamentals (LGVN)
| Total Revenue | $1.22M |
|---|---|
| Revenue Growth (YoY) | +4.50% |
| Gross Margin | +65.13% |
| Operating Margin | -1149.50% |
| Profit Margin | +0.00% |
| ROE | -135.18% |
| Debt / Equity | 4.67 |
| Current Ratio | 3.88 |
| Total Cash | $15.76M |
| Total Debt | $748,000 |
| Free Cash Flow | $-10.45M |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financial Health Score (LGVN)
Nexqual rates Longeveron Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:51 UTC.
| Growth | Critical — Revenue -50% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $16M cash, no debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -135%, ROA -67.4% |
Ownership (LGVN)
| Insider Ownership | +9.32% |
|---|---|
| Institutional Ownership | +11.95% |
| Shares Outstanding | 30.15M |
| Float | 25.86M |
| Short % of Float | +5.47% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Leadership (LGVN)
Longeveron Inc. is led by Joshua Michael Hare FACC (age 62), Co-Founder, Chief Science Officer & Executive Chairman, per Nexqual as of July 25, 2026 at 03:51 UTC.
| Co-Founder, Chief Science Officer & Executive Chairman | Joshua Michael Hare FACC (age 62) |
|---|
Major Backers & Investors (LGVN)
Notable institutional backers of Longeveron Inc. include Millennium Management, Adar1 Capital Management, LLC , Jane Street Group, LLC, according to Nexqual as of July 25, 2026 at 03:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 1.48% |
| Adar1 Capital Management, LLC | 0.66% |
| Jane Street Group, LLC | 0.62% |
| Fidelity | 0.55% |
| HRT Financial LP | 0.39% |
| Beacon Pointe Advisors, LLC | 0.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.73% |
| BlackRock | 0.74% |
| Geode Capital | 0.68% |
| State Street | 0.15% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
From Longeveron Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
- Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ISPC | iSpecimen Inc. | USD 1.97 | ▼ 12.44% |
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:51 UTC. This page is informational and not investment advice.